Annual report pursuant to Section 13 and 15(d)

Acquisition Purchase Price Allocation (Details)

v3.3.1.900
Acquisition Purchase Price Allocation (Details) - USD ($)
$ in Thousands
 6 Months Ended
Oct. 31, 2014
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Aug. 31, 2013
Business Acquisition [Line Items]          
Subordinated note payable   $ 10,700      
Contingent consideration     $ 18,549 $ 26,542 $ 500
Goodwill     0 15,545  
Regulatory Liability, Noncurrent     $ 2,500 $ 2,500  
RedPath Integrated Pathology, Inc          
Business Acquisition [Line Items]          
Cash $ 13,572        
Cash 22,066        
Common stock 1,820        
Contingent consideration 23,886        
Total consideration 44,975        
Goodwill 15,666        
Acquired intangible assets 34,492        
Current assets 5,465        
Business Combination, Indemnification Assets, Amount as of Acquisition Date 2,500        
Other long-term assets 366        
Current liabilities (4,809)        
Regulatory Liability, Noncurrent (2,500)        
Deferred income tax liability (6,205)        
Total acquired assets 44,975        
Diagnostic Test - Pancreas | RedPath Integrated Pathology, Inc          
Business Acquisition [Line Items]          
Acquired intangible assets 16,141        
Diagnostic Test - Barrett's RedPath | RedPath Integrated Pathology, Inc          
Business Acquisition [Line Items]          
Acquired intangible assets 18,351        
Notes Payable, Other Payables          
Business Acquisition [Line Items]          
Subordinated note payable 11,000        
Notes Payable, Other Payables | RedPath Integrated Pathology, Inc          
Business Acquisition [Line Items]          
Subordinated note payable $ 7,517